TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 65 years~* Age \< 65 but not eligible to high-dose chemotherapy and autologous stem cell transplantation~* Biopsy-proven DLBCL relapsed to previous combination chemotherapy regimen ± rituximab~* PR (Partial Response) or CR (Complete Response) to second-line chemotherapy (ICE or DHAP/DHAOx or MINE regimen) + rituximab~* ECOG (Eastern Cooperative Oncology Group) performance status score \< 4~* Female of childbearing potential (FCBP) must demonstrate to practice a proper contraception to avoid any pregnancy risk during the study and at least 28 days after the discontinuation of the study~* Male subjects must agree to practice a proper contraception during any sexual contact with females childbearing potential~Exclusion Criteria:~* CNS (Central Nervous System) involvement~* Prior ASCT~* TTP (Time To Progression) \<6 months after first-line therapy~* Use of experimental drugs during second-line salvage chemotherapy~* Severe concomitant illnesses / medical conditions (e.g. impaired respiratory and/or cardiac function, uncontrolled diabetes mellitus )~* Active infectious disease~* HIV, HBV (Hepatitis B Virus) or HCV (Hepatitis C Virus) - positivity~* Impaired liver function (Bilirubin \>2 x upper normal limit; ALT (alanine aminotransferase) /AST (aspartate aminotransferase) /GGT (γ-glutamyltransferase) \> 3 x upper normal limit) at one month from salvage chemotherapy conclusion~* Impaired renal function (creatinine clearance \<50 ml/min) at one month from salvage chemotherapy conclusion~* Absolute neutrophil count (ANC) \<1000/microL~* Platelet count \<75.000 /mm3~* Hemoglobin \<9 g/dL~* Non-co-operative behaviour or non-compliance~* Psychiatric diseases or conditions that might impair the ability to give informed consent~* Pregnant or lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide (Type: EXPERIMENTAL): single-agent lenalidomide 25 mg once daily for 21 days out of 28, as maintenance treatment after the end of second-line chemotherapy until progression of disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged over 18 years old;~* Patient should be scheduled and eligible for surgery because of a clinical diagnosis of cancer of the colon, rectum or cancer of the pancreas;~* Both pancreatic and colorectal cancer patients: Circulating plasma CEA ≥ the upper limit of normal range (eg ≥ 3.0 ng / ml);~* Patient suffering from recurrences and metastasis of colorectal cancer: Rising circulating plasma CEA~* Patients should be capable and willing to give informed consent before study specific procedures.~Exclusion Criteria:~* Anticancer therapy (e.g. chemotherapy, radiotherapy (except for routine pre-operative radiotherapy for colorectal cancer), targeted therapy, concomitant systemic immune therapy, or any experimental therapy) within 4 weeks before inclusion;~* History of a clinically significant allergy;~* Circulating plasma concentration CEA ≥ 300 ng / ml;~* Other malignancies either currently active or diagnosed in the last 5 years, except adequately treated in situ carcinoma of the cervix and basal or squamous cell skin carcinoma;~* Patients pregnant or breastfeeding (pregnancy should be ruled out by an assay of βhCG plasma within 4±1 weeks prior to administration of the conjugate), lack of effective contraception in male or female patients with reproductive potential;~* Laboratory abnormalities defined as:~Colorectal cancer patients only:~* Aspartate AminoTransferase, Alanine AminoTransferase, Gamma Glutamyl Transferase) or Alkaline Phosphatase levels above 5 times the or;~* Total bilirubin above 2 times the Upper Limit Normal (ULN) or; Both pancreatic and colorectal cancer patients:~* Serum creatinine above 1.5 times the ULN or;~* Absolute neutrophils counts below 1.5 x 109/L or;~* Platelet count below 100 x 109/L or;~* Hemoglobin below 4 mmol/L (females) or below 5 mmol/l (males);~* Known positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAG) or hepatitis C virus (HCV) antibody or patients with untreated serious infections;~* Any condition that the investigator considers to be potentially jeopardizing the patients' wellbeing or the study objectives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SGM-101 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must sign an Informed Consent Form~* In remission from past HE~* Uses appropriate birth control measures~* More than or equal to 18 years of age~* Must have potential to benefit from treatment~* Recent prior HE episodes~* Capable and willing to comply with all study procedures~* Participant has personal support available~* Has a certain Model End Stage Liver Disease (MELD) score~* Recent transjugular intrahepatic portosystemic shunt (TIPS) placement or revision~Exclusion Criteria:~* Significant medical conditions, medical conditions that may impact study participation, or Investigator decision not to include~* Allergies to the study drug or similar drugs~* Laboratory abnormalities~* Recent participation in another clinical trial~* History of non-compliance~* Pregnant or at risk of pregnancy, or is lactating~* Recent alcohol consumption~* Active bacterial or viral Infections~* Bowel issues~* Active malignancy~* On a prohibited medication~* Liver transplant expected in near term~* Lactulose intolerance~* Participant shows presence of intestinal obstruction or has inflammatory bowel disease~* Ongoing or recent GI bleed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rifaximin (Type: EXPERIMENTAL): Participants were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation.
- Placebo (Type: PLACEBO_COMPARATOR): Participants were administered a single matching placebo tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed colon carcinoma, AJCC/UICC Stage III (Dukes stage C)~* Complete tumor resection; Patients operated with curative intent and with no macroscopic or microscopic evidence for remaining tumor who can be randomized to either treatment arm within 8 weeks after surgery. As this is an adjuvant trial patients should never have had any evidence of metastatic disease (including presence of tumor cells in the ascites).~* Have a life expectancy of at least 5 years~Exclusion Criteria:~* Pregnant or lactating women~* Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study~* Previous cytotoxic chemotherapy, radiotherapy or immunotherapy, for the currently treated colon cancer~* Patients who have not completely recovered from surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5-Fluorouracil/Leucovorin (5-FU/LV) (Type: ACTIVE_COMPARATOR): Participants were given one of two regimens (each participating center prespecified which regimen they would use for all patients at that center): i) Mayo Clinic regimen group: LV 20 mg/m\^2 IV bolus injection + 5-FU 425 mg/m\^2 IV bolus injection daily on Days 1-5 of a four-week cycle, for a total of six cycles (24 weeks), or; ii) Roswell Park regimen group: LV 500 mg/m\^2 by two-hour IV infusion + 5-FU 500 mg/m\^2 IV bolus injection one hour after the start of the LV infusion on Day 1 of Weeks 1 to 6 of each eight-week cycle, for a total of four cycles (32 weeks).
- Capecitabine in Combination with Oxaliplatin (XELOX) (Type: EXPERIMENTAL): Capecitabine was administered as an oral twice daily outpatient intermittent treatment (3-week cycles consisting of two weeks of treatment followed by one week without treatment) combined with intravenous (IV) oxaliplatin on Day 1 of each cycle. Capecitabine was administered orally at a dose of 1000 mg/m\^2 twice-daily (equivalent to a total daily dose of 2000 mg/m\^2) with the first dose given during the evening of Day 1 and last dose given during the morning of Day 15. Oxaliplatin was administered as a 130 mg/m\^2 IV infusion over two hours on Day 1 of each cycle. The XELOX combination was administered for a total of eight cycles (24 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Pioglitazone on Insulin Sensitivity in Healthy Overweight and Obese Males (MK-0000-170)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a BMI of greater than 28 kg/m\^2 and less than or equal to 38 kg/m\^2~* Subject has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months~* Subject is willing to avoid major dietary changes for the duration of the study~Exclusion Criteria:~* Subject has history of diabetes (Type 1, Type 2 or steroid-induced)~* Subject has a history of hypersensitivity to pioglitazone or other thiazolidinediones~* Subject has a history of liver disease, other than non-alcoholic fatty liver disease or non-alcoholic steatohepatitis~* Subject has a history of congestive heart failure~* Subject has a active or past history of atherosclerotic heart disease, heart failure, osteoporosis, osteopenia, recurrent bone fractures, or anemia~* Subject has a history of stroke, chronic seizures, or major neurological disorder~* Subject has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological or renal abnormalities or diseases~* Subject has a history of neoplastic disease within the past 5 years

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Pioglitazone 30 mg (Type: ACTIVE_COMPARATOR): Pioglitazone 30 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate Pregabalin In Patients With Painful Diabetic Peripheral Neuropathy (DPN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Type 1 or 2 diabetes mellitus.~* Diagnosis of painful DPN for at least 12 months but less than 5 years in duration.~Exclusion Criteria:~* Neurologic Disorders unrelated to diabetic neuropathy that may confuse or confound the assessment of neuropathic pain.~* Presence of any severe pain associated with conditions other than DPN that may confuse or confound the assessment of neuropathic pain.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quantifying the Efficacy and Role of Service Dogs for Military Veterans With PTSD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria for veterans into the study will include:~* Applied for and approved to receive a dog from K9s For Warriors~* Military service on or after September 11, 2001~* Honorable discharge or current honorable service~* Diagnosis of PTSD~* No conviction of any crimes against animals.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Service Dog (Type: EXPERIMENTAL): Participants in the service dog arm will receive unrestricted, non-study usual care, in addition to a trained service dog.
- Waitlist Control (Type: NO_INTERVENTION): Participants in the control arm will receive unrestricted, non-study usual care, while on the waitlist for a service dog.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Aripiprazole in Patients With Acute Bipolar Mania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with Bipolar I Disorder and a diagnosis of acute mania will be considered for this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: PLACEBO_COMPARATOR): None
- B (Type: EXPERIMENTAL): None
- C (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with type 2 diabetes and hypertension~* Medically stable~* On at least 1 (and up to 2) oral diabetes drugs~* And up to 2 medicines for blood pressure control~Exclusion Criteria:~* Participants with type 1 diabetes~* Heart attack~* Stroke~* Uncontrolled blood pressure~* Significant kidney disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to ertugliflozin (resembling either 1 mg or 5 mg), placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days.
- Ertugliflozin 1 mg (Type: EXPERIMENTAL): Ertugliflozin 1 mg, placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days
- Ertugliflozin 5 mg (Type: EXPERIMENTAL): Ertugliflozin 5 mg, placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days
- Ertugliflozin 25 mg (Type: EXPERIMENTAL): Ertugliflozin 25 mg, placebo to ertugliflozin (resembling either 1 mg or 5 mg), and placebo to HCTZ once daily for 28 days
- HCTZ 12.5mg (Type: ACTIVE_COMPARATOR): HCTZ 12.5 mg, placebo to ertugliflozin (resembling either 1 mg or 5 mg), and placebo to ertugliflozin (resembling 25 mg) once daily for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females, aged ≥ 18 years at time of consent.~* Have a diagnosis of Psoriatic Arthritis (PSA, by any criteria) of ≥ 6 months duration.~* Meet the Classification Criteria for Psoriatic Arthritis (CASPAR) at time of screening.~* Must have been inadequately treated by disease-modifying antirheumatic drugs (DMARDs)~* May not have axial involvement alone~* Concurrent treatment allowed with methotrexate, leflunomide, or sulfasalazine~* Have ≥ 3 swollen AND ≥ 3 tender joints.~* Males \& Females must use contraception~* Stable dose of nonsteroidal anti-inflammatory drugs (NSAIDs), narcotics and low dose oral corticosteroids allowed.~Exclusion Criteria:~* Pregnant or breast feeding.~* History of allergy to any component of the investigational product.~* Hepatitis B surface antigen and/or Hepatitis C antibody positive at screening.~* Therapeutic failure on \> 3 agents for PsA or \> 1 biologic tumor necrosis factor (TNF) blocker

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apremilast 20 mg (Type: EXPERIMENTAL): 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
- Apremilast 30mg (Type: EXPERIMENTAL): 30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
- Placebo + 20 mg Apremilast (Type: PLACEBO_COMPARATOR): Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
- Placebo + 30 mg Apremilast (Type: PLACEBO_COMPARATOR): Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Investigating the Effect of NN1250 in Young and Elderly Subjects With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18-35 years (both inclusive) (young group) or at least 65 years (geriatric group)~* Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months~* Body mass index 18.0-28.0 kg/m\^2 (both inclusive)~Exclusion Criteria:~* Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening~* Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day)~* Not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- IDeg (Type: EXPERIMENTAL): None
- IGlar (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rifaximin in Patients With Gastroesophageal Variceal Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 y.o. ≤age≤75 y.o.;~* Cirrhotic gastroesophageal variceal bleeding underwent endoscopic treatment (include esophageal varices ligation, endoscopic injection sclerosis and gastric N- butyl-cyanoacrylate injection).~Exclusion Criteria:~* age \<18 y.o. or age \> 75 y.o.;~* Never had the variceal bleeding episode before;~* Do not have endoscopic treatment;~* Combined with other malignant tumors (not exclude patients with hepatocellular carcinoma who don't need treatment at the moment);~* Known infection after endoscopic treatment (Fever, microbial cultures positive, et al.)~* Massive ascites or combined with other high-risk factors that require prophylaxis use of antibiotics.~* Acute variceal bleeding within 5 days.~* Refuse to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Rifaximin Treatment Group (Type: EXPERIMENTAL): Rifaximin 400mg bid for 2 months,
- Control Group (Type: NO_INTERVENTION): Receive routine endoscopic treatment without having rifaximin for 2 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete